Skip to main content

Table 1 Characteristics of the included trials

From: mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis

Trials

 

Multicentre trial

 

Induction

mTOR-I group

MPA group

Follow-up (years)

Country

No.(male)

Maintenance

Dose/target level

Maintenance

Dose/target level

Vitko et al. 2005

Multiple

Yes

588 (380)

None

EVE + CsA + ST

1.5 mg/d

MMF + CsA + ST

2 g/d

3

3 mg/d

Lorber et al. 2005

Multiple

Yes

583 (365)

Bas

EVE + RD-CsA + ST

1.5 mg/d

MMF + CsA + ST

2 g/d

3

3 mg/d

Mendez et al. 2005

America

Yes

361 (246)

None

SRL + TAC + ST

2 mg/d

MMF + TAC + ST

2 g/d

1

Vitko et al. 2006

Multiple

Yes

977 (624)

None

SRL + TAC + ST

0.5 mg/d

MMF + TAC + ST

1 g/d

0.5

2 mg/d

Kumar et al. 2008

America

No

200 (140)

Bas

SRL + TAC

5-10 ng/ml

MMF + TAC

1-3 u/ml

5

SRL + CsA

5-10 ng/ml

MMF + CsA

1-3 u/ml

Sampaio et al. 2008

Brazil

Yes

100 (69)

None

SRL + TAC + ST

2 mg/d

MMF + TAC + ST

2 g/d

1

Gurp et al. 2010

Multiple

Yes

634 (408)

None

SRL + RD-TAC + ST

1 mg/d

MMF + TAC + ST

1 mg/d

0.5

Guerra et al. 2011

America

No

150 (99)

Dac

SRL + TAC + ST

6-10 ng/ml

MMF + TAC + ST

2 g/d

8

SRL + CsA + ST

6-10 ng/ml

Chhabra et al. 2012

America

No

82 (50)

Bas

SRL + TAC

7-10 ng/ml

MMF + TAC

2 g/d

8.5

Crbrik et al. 2013

Multiple

Yes

833 (557)

Bas

EVE + RD-CsA ± ST

1.5 mg/d

Ec-MPS + CsA ± ST

1.44 g/d

2

3 mg/d

Takahashi 2013

Japan

Yes

122 (83)

Bas

EVE + RD-CsA + ST

3-8 ng/ml

MMF + CsA + ST

2 g/d

1

  1. Bas basiliximab; Dac daclizumab; EVE everolimus; SRL sriolimus; TAC tacrolimus; CsA ciclosporin; ST steroid; MMF mycophenloate mofetil; Ec-MPS enteric-coated mycophenolate sodium
  2. RD-CNI, patients in mTOR-I group received a reduced dose of ciclosporin/tacrolimus compared with the MPA group